Heart failure & cardiomyopathies
Frequency of screening for cardiac allograft vasculopathy: warranty period of initial low risk positron emission tomography
Main finding · Progression to CAV 2/3Result — go to the resultOdds ratio 12.4 95% CI 3.06–50.3Authors' conclusion
The rate of progression to moderate-severe CAV at 1 year after the lowest-risk PET/CT is low, but approximately 1/6 patients with PET CAV 1 progress to CAV 2/3.
Study context
- Population
- Heart transplant patients with no history of cardiac allograft vasculopathy (CAV) 2/3 and a low-risk initial screening PET/CT (CAV 0/1)
- Participants
- 231 patients
- Exposure
- PET CAV 1 vs PET CAV 0 on initial screening PET/CT
- Outcome
- Progression to CAV 2/3 as part of an annual screening programme
- Follow-up
- Within 6-18 months of initial scan
Main finding
Progression to CAV 2/3 · median 374 days (IQR 363-433)
Odds ratio
12.4
95% CI 3.06–50.3
PET CAV 1 vs PET CAV 0
OR 12.4 (95% CI 3.06–50.3)
As reported in the abstract
- Patients progressing to CAV 2/3 (whole cohort)
- 4.3%
Observational data: associations, not effects.
Further findings
Progression to CAV 2/3 by initial PET CAV grade
Original publication
Frequency of screening for cardiac allograft vasculopathy: warranty period of initial low risk positron emission tomography. Eur Heart J Cardiovasc Imaging. Published 12 January 2024. doi:10.
Summarised from the published abstract; every number is checked against it